Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury.
Muizelaar
J P
JP
Division of Neurosurgery, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0631, USA.
D000328:Adult; D000818:Animals; D002417:Cattle; D006259:Craniocerebral Trauma / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D016166:Free Radical Scavengers / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D010919:Placebos; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity*; D012044:Regression Analysis; D013482:Superoxide Dismutase / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity*; D013997:Time Factors; D016896:Treatment Outcome
D016166:Free Radical Scavengers; D010919:Placebos; D011092:Polyethylene Glycols; D013482:Superoxide Dismutase; C063471:polyethylene glycol-superoxide dismutase